JPRN-UMIN000010942已完成未知
Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer. - Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer.
Tokyo Women's Medical University0 个研究点目标入组 12 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) No hypercalcemia that require medication, No C-reactive protein with an infectious disease that requires medication, No active infection with hepatitis virus or HIV, No current treatment with steroids and immunosuppressive drugs, No poorly controlled DM or heart failure or arrhythmia, No autoimmune disease and interstitial pneumonia, No other malignancy, No bone of organ transplant recipient, Not pregnant nor nursing, No mental disorder 2) Other patients judged to be ineligible by the attending investigators were also excluded from the study
研究者
相似试验
进行中（未招募）
不适用
Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer. - Not applicableBladder Cancer Stage 1 without Cancer in SituPatients will have transitional-cell carcinoma of the bladder, clinical TNM stage Ta or T1 and histologic grade G1 or G2 before transurethral resection.MedDRA version: 9Level: PTClassification code 10005009EUCTR2006-002372-18-NLSpectrum Pharmaceuticals, Inc.20
招募中
1 期
Investigation of the safety and efficacy of the optimized measles virus vaccine in bladder tumor healingIRCT20230903059342N1Kian Gen Azma Company10
尚未招募
2 期
Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitisJPRN-UMIN000006387niversity of Tokushima30
进行中（未招募）
不适用
A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinomarinary bladder cancer is an attractive target for immunostimulating gene therapy because it is sensitive for immunotherapy as demonstrated by the life-prolonging effect of bacillus Calmette-Guérin (BCG) instillations. Phase I: Patients with infiltrative cancer of the urinary bladder and scheduled for cystectomy.Phase IIa: Patients with non-infiltrative cancer of the urinary bladder, stages Ta and scheduled for resectionEUCTR2006-000985-34-SEClinical Immunology Division30
招募中
1 期
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2High-risk Non-muscle Invasive Bladder CancerNCT06378242RemeGen Co., Ltd.24